PropertyValue
?:abstract
  • Camelid-derived and synthetic single-domain antibodies (sdAbs) are emerging as potent weapons against the novel coronavirus, SARS-CoV-2. SdAbs are small, compact, thermostable immunoglobulin elements capable of binding targets with sub-nanomolar affinities. By leveraging the power of phage- and yeast surface-display technologies, rare sdAbs can be isolated from highly diverse and complex antibody libraries. Once in hand, sdAbs can be engineered to improve binding affinity, avidity, target specificities, and bio-distribution. In this Opinion piece, we highlight a series of sophisticated studies describing the identification of ultrapotent sdAbs directed against the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein. We discuss the possible applications of these antibodies in the global fight against COVID-19.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1016/j.tim.2020.12.006
?:journal
  • Trends_Microbiol
?:license
  • els-covid
?:pdf_json_files
  • document_parses/pdf_json/23b7608f06115c5302c55dba83487215a25f194a.json
?:pmcid
?:pmid
?:pmid
  • 33446406.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Slaying SARS-CoV-2 One (Single-Domain) Antibody at a Time
?:type
?:year
  • 2020-12-16

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/jdq859xc>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/jdq859xc>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all